VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 365 filers reported holding VALEANT PHARMACEUTICALS INTL in Q3 2016. The put-call ratio across all filers is 0.92 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2017 | $732,000 | -29.4% | 66,400 | -7.0% | 0.04% | -39.1% |
| Q4 2016 | $1,037,000 | -38.4% | 71,400 | +4.1% | 0.07% | -34.9% |
| Q3 2016 | $1,684,000 | +26.5% | 68,600 | +3.8% | 0.11% | +7.1% |
| Q2 2016 | $1,331,000 | -40.8% | 66,100 | -22.7% | 0.10% | -47.3% |
| Q1 2016 | $2,249,000 | -73.6% | 85,500 | +2.2% | 0.19% | -70.9% |
| Q4 2015 | $8,508,000 | -57.6% | 83,700 | -25.6% | 0.64% | -60.4% |
| Q3 2015 | $20,068,000 | -52.3% | 112,500 | -40.6% | 1.63% | -46.9% |
| Q2 2015 | $42,042,000 | +36.6% | 189,250 | +22.1% | 3.07% | +6.6% |
| Q1 2015 | $30,786,000 | +240.1% | 155,000 | +145.1% | 2.88% | +172.0% |
| Q4 2014 | $9,052,000 | +23.2% | 63,250 | +12.9% | 1.06% | -6.9% |
| Q3 2014 | $7,347,000 | +5.4% | 56,000 | +1.4% | 1.14% | -9.0% |
| Q2 2014 | $6,968,000 | -0.3% | 55,250 | +4.2% | 1.25% | -22.5% |
| Q1 2014 | $6,987,000 | +26.6% | 53,000 | +12.8% | 1.61% | -18.2% |
| Q4 2013 | $5,518,000 | – | 47,000 | – | 1.97% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Brave Warrior Advisors | 6,050,442 | $763,082,000 | 30.78% |
| LeVasseur Capital Partners LLC | 190,404 | $24,014,000 | 29.50% |
| FARLEY CAPITAL L.P. | 333,081 | $42,008,000 | 27.09% |
| Ruane, Cunniff & Goldfarb | 34,298,384 | $4,325,712,000 | 23.07% |
| ValueAct Holdings | 18,923,877 | $2,386,679,000 | 17.64% |
| Tesuji Partners | 1,368,040 | $172,537,000 | 17.22% |
| Brahman Capital Corp. | 3,902,877 | $492,231,000 | 13.63% |
| Arrow Capital Management, LLC | 197,500 | $24,909,000 | 13.60% |
| Hound Partners | 2,851,175 | $359,590,000 | 13.45% |
| Ratan Capital Management LP | 731,960 | $92,315,000 | 13.09% |